Is Ibogaine Legal in Maine? (2026)

Instrument

Schedule X drugs

Source

https://www.mainelegislature.org/legis/statutes/17-a/title17-Asec1102.html

Retrieved

2026-10-31

Fingerprint

6d30749a8f077913

2. 

Schedule X:
                                     

A.

Unless listed or described in another schedule, any of the following drugs having depressant effect on the central nervous system
                                     

                                            (1)

Chlorhexadol
                                     

                                            (2)

Sulfondiethylmethane
                                     

                                            (3)

Sulfonethylmethane
                                     

                                            (4)

Sulfonmethane
                                     

[PL 1975, c. 499, §1 (NEW).]

B.

Nalorphine;
                                     

[PL 1975, c. 499, §1 (NEW).]

C.

Unless listed in another schedule, any of the following hallucinogenic drugs, or their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation
                                     

                                            (1)

Bufotenine
                                     

                                            (2)

Ibogaine
                                     

                                            (3)

Mescaline, including but not limited to peyote
                                     

                                            (4)

N-methyl-3-piperidyl benzilate
                                     

                                            (5)

N-ethyl-3-piperidyl benzilate
                                     

                                            (6)

Psilocybin
                                     

                                            (7)

Psilocyn
                                     

                                            (8)

Hashish;
                                     

[PL 1977, c. 649, §2 (AMD).]

D.

                                     

[PL 2001, c. 419, §7 (RP).]

E.

Methaqualone or its salts;
                                     

[PL 1975, c. 499, §1 (NEW).]

F.

Methprylon;
                                     

[PL 1975, c. 499, §1 (NEW).]

G.

Glutethimide.
                                     

[PL 1975, c. 499, §1 (NEW).]

H.

Unless listed or described in another schedule, the following hallucinogenic drugs or their salts, isomers and salts of isomers whenever the existence of the salts, isomers and salts of isomers is possible within the specific chemical designation:
                                     

                                            (5)

Diethyltryptamine, DET;
                                     

                                            (6)

Dimethyltryptamine, DMT;
                                     

                                            (7)

Dipropyltryptamine, DPT; and
                                     

                                            (12)

Alpha-ethyltryptamine, AET.
                                     

[PL 2001, c. 419, §8 (AMD).]

I.

                                     

[PL 1989, c. 924, §5 (RP).]

J.

                                     

[PL 1989, c. 924, §6 (RP).]

K.

Diethylpropion or its salts;
                                     

[PL 2001, c. 419, §9 (AMD).]

L.

Gamma hydroxybutyrate, GHB, and its salts, isomers and salts of isomers;
                                     

[PL 2001, c. 419, §10 (NEW).]

M.

Ketamine and its salts, isomers and salts of isomers; and
                                     

[PL 2001, c. 419, §10 (NEW).]

N.

The following substances, if intended for human ingestion:
                                     

                                            (1)

Gamma butyrolactone, GBL, and its salts, isomers and salts of isomers; or
                                     

                                            (2)

One, 4-butanediol, BD, and its salts, isomers and salts of isomers.
                                     

[PL 2001, c. 419, §10 (NEW).]

[PL 2001, c. 419, §§7-10 (AMD).]

Instrument

Schedules W, X, Y and Z (Schedule Z)

Source

https://legislature.maine.gov/statutes/17-A/title17-Asec1102.html

Retrieved

2026-10-31

Fingerprint

0b5c67fa52202ef0

Schedule Z:
                                     

A.

All prescription drugs other than those included in schedules W, X or Y;
                                     

[PL 1975, c. 499, §1 (NEW).]

B.

Marijuana;
                                     

[PL 1975, c. 499, §1 (NEW).]

C.

All nonprescription drugs other than those included in schedules W, X or Y as the Maine Board of Pharmacy shall duly designate;
                                     

[PL 1989, c. 924, §7 (AMD); PL 1997, c. 245, §19 (AMD).]

D.

Butyl nitrite or isobutyl nitrite;
                                     

[PL 2011, c. 428, §5 (AMD); PL 2011, c. 428, §9 (AFF).]

E.

A methamphetamine precursor drug; and
                                     

[PL 2011, c. 428, §6 (AMD); PL 2011, c. 428, §9 (AFF).]

F.

[PL 2013, c. 341, §5 (RP).]

G.

Synthetic cannabinoids, including:
                                     

                                            (1)

Tetrahydrocannabinols that are naturally contained in a plant of the genus Cannabis or a cannabis plant, excluding tetrahydrocannabinols contained in hemp as defined in
Title 7, section 2231, subsection 1‑A, paragraph D
, as well as synthetic equivalents of the substances contained in the cannabis plant or in the resinous extracts of cannabis or synthetic substances, derivatives and their isomers with similar chemical structure and pharmacological activity, including the following:
                                     

                                            (a)

Delta-1 cis or trans tetrahydrocannabinol and their optical isomers;
                                     

                                            (b)

Delta-6 cis or trans tetrahydrocannabinol and their optical isomers; or
                                     

                                            (c)

Delta-3,4 cis or trans tetrahydrocannabinol and their optical isomers;
                                     

                                            (2)

Naphthoylindoles, including any compound containing a 3-(1-naphthoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including the following:
                                     

                                            (a)

1-Pentyl-3-(1-naphthoyl)indole or JWH-018 or AM-678;
                                     

                                            (b)

1-Butyl-3-(1-napthoyl)indole or JWH-073;
                                     

                                            (c)

1-Pentyl-3-(4-methoxy-1-naphthoyl)indole or JWH-081;
                                     

                                            (d)

1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole or JWH-200;
                                     

                                            (e)

1-Propyl-2-methyl-3-(1-naphthoyl)indole or JWH-015;
                                     

                                            (f)

1-Hexyl-3-(1-naphthoyl)indole or JWH-019;
                                     

                                            (g)

1-Pentyl-3-(4-methyl-1-naphthoyl)indole or JWH-122;
                                     

                                            (h)

1-Pentyl-3-(4-ethyl-1-naphthoyl)indole or JWH-210;
                                     

                                            (i)

1-Pentyl-3-(4-chloro-1-naphthoyl)indole or JWH-398; or
                                     

                                            (j)

1-(5-fluoropentyl)-3-(1-naphthoyl)indole or AM-2201;
                                     

                                            (3)

Naphthylmethylindoles, including any compound containing a H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including the following:
                                     

                                            (a)

1-Pentyl-1H-indol-3-yl-(1-naphthyl)methane or JWH-175; or
                                     

                                            (b)

1-Pentyl-1H-3-yl-(4-methyl-1-naphthyl)methane or JWH-184;
                                     

                                            (4)

Naphthoylpyrroles, including any compound containing a 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including (5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone or JWH-307;
                                     

                                            (5)

Naphthylideneindenes or naphthylmethylindenes, including any compound containing a naphthylideneindene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent, including E-1-[1-(1-Naphthalenylmethylene)-1H-inden-3-yl]pentane or JWH-176;
                                     

                                            (6)

Phenylacetylindoles, including any compound containing a 3-phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent, including the following:
                                     

                                            (a)

1-(2-cyclohexylethyl)-3-(2-methoxypheylacetyl)indole or RCS-8;
                                     

                                            (b)

1-Pentyl-3-(2-methoxyphenylacetyl)indole or JWH-250;
                                     

                                            (c)

1-Pentyl-3-(2-methylphenylacetyl)indole or JWH-251; or
                                     

                                            (d)

1-Pentyl-3-(2-chlorophenylacetyl)indole, or JWH-203;
                                     

                                            (7)

Cyclohexylphenols, including any compound containing a 2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not substituted in the cyclohexyl ring to any extent, and their isomers with similar chemical structure and pharmacological activity, including the following:
                                     

                                            (a)

5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol or CP 47,497;
                                     

                                            (b)

5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol or Cannabicyclohexanol or CP 47,497-C8 homologue; or
                                     

                                            (c)

5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-phenol or CP 55,490;
                                     

                                            (8)

Benzoylindoles, including any compound containing a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent, including the following:
                                     

                                            (a)

1-Pentyl-3-(4-methoxybenzoyl)indole or RCS-4;
                                     

                                            (b)

1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole or AM-694; or
                                     

                                            (c)

(4-Methoxyphenyl)-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-y]methanone or WIN-48,098 or Pravadoline; and
                                     

                                            (9)

The following other unclassified synthetic cannabinoids:
                                     

                                            (a)

(6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol or HU-210;
                                     

                                            (b)

(6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol or Dexanabinol or HU-211;
                                     

                                            (c)

2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl-1-naphthalenylmethanone or WIN 55,212-2; or
                                     

                                            (d)

(1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone or XLR-11.
                                     

[RR 2021, c. 2, Pt. A, §36 (COR).]

[RR 2021, c. 2, Pt. A, §36 (COR).]

5. 

[PL 2013, c. 194, §9 (RP).]

Instrument

Unlawful use or possession of inhalants

Source

https://legislature.maine.gov/statutes/22/title22sec2383-C.html

Retrieved

2026-10-31

Fingerprint

85f45d1bc21b2fa9

§2383-C. Unlawful use or possession of inhalants

1. 
                                Prohibited acts. 

A person may not intentionally or knowingly:
                                     

A.

Inhale, ingest, apply or smell the gases, vapors or fumes of any gas, hazardous inhalant, substance containing a volatile chemical or substance containing a chemical material capable of releasing toxic vapors or fumes for the purpose of causing intoxication, euphoria, inebriation, excitement, stupefaction or the dulling of that person’s brain or nervous system; or
                                     

[PL 1997, c. 325, §1 (NEW).]

B.

Possess any gas, hazardous inhalant, substance containing a volatile chemical or substance containing a chemical material capable of releasing toxic vapors with the intent to violate
paragraph A
.
                                     

[PL 1997, c. 325, §1 (NEW).]

[PL 1997, c. 325, §1 (NEW).]

2. 
                                Exclusions. 

Nothing in this section applies to the inhalation of anesthesia for medical or dental purposes or the inhalation of the vapors or fumes of an alcoholic beverage, the sale and consumption of which is authorized by law.
                                     

[PL 1997, c. 325, §1 (NEW).]

3. 
                                Presumption regarding violations. 

Proof that a person intentionally or knowingly inhaled, ingested, applied or used a substance in a manner contrary to the directions for use, cautions or warnings on a label of a container of the substance gives rise to a presumption that the person violated
subsection 1
.
                                     

[PL 1997, c. 325, §1 (NEW).]

4. 
                                Presumption regarding ingredients. 

For the purposes of this section, it is presumed that the ingredients in a container are, in fact, the ingredients listed on a label of the container or the ingredients listed for that substance in databases maintained or relied upon by a poison control center certified by a national association of poison control centers.
                                     

[PL 1997, c. 325, §1 (NEW).]

5. 
                                Penalties. 

A person who violates this section commits a civil violation for which a forfeiture, which may not be suspended except as provided in
subsection 6
, must be adjudged as follows:
                                     

A.

Not less than $100 or more than $300 for the first offense;
                                     

[PL 1997, c. 325, §1 (NEW).]

B.

Not less than $200 or more than $500 for the 2nd offense; and
                                     

[PL 1997, c. 325, §1 (NEW).]

C.

Five hundred dollars for the 3rd and each subsequent offense.
                                     

[PL 1997, c. 325, §1 (NEW).]

[PL 1997, c. 325, §1 (NEW).]

6. 
                                Additional orders. 

In addition to the civil forfeitures required by
subsection 5
, the judge may order the person to perform specified work for the benefit of the State, the municipality or other public entity or charitable institution or to undergo evaluation, education or treatment with a licensed social worker or a licensed substance use disorder counselor.  If the judge orders the person to perform specified work or to undergo evaluation, education or treatment, the judge may suspend a forfeiture imposed pursuant to
subsection 5
.
                                     

[PL 2017, c. 407, Pt. A, §75 (AMD).]

                        SECTION HISTORY

PL 1997, c. 325, §1 (NEW). PL 2017, c. 407, Pt. A, §75 (AMD).